cytarabine and s 1033

cytarabine has been researched along with s 1033 in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's4 (57.14)24.3611
2020's2 (28.57)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Cleverley, J1
Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C1
Caruso, M; de Campos-Lima, PO; Ghani, K; Naud, JS1
Baldus, CD; Bock, J; Hofmann, WK; Kühl, AA; Mochmann, LH; Neumann, M; Nowak, V; Ortiz-Tanchez, J; von der Heide, EK1
Iriyama, N; Kawaguchi, T; Kirito, K; Kizaki, M; Shimoda, K; Takahashi, N1
Bin, T; Chen, S; Chen, X; Cheng, J; Liao, Y; OUYang, J; Zou, W1

Reviews

2 review(s) available for cytarabine and s 1033

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN).
    International journal of hematology, 2020, Volume: 112, Issue:3

    Topics: Cytarabine; Dasatinib; Drug Monitoring; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Pyrimidines

2020

Other Studies

5 other study(ies) available for cytarabine and s 1033

ArticleYear
American Society of Clinical Oncology--42nd annual meeting. Poster presentations on leukemia and cytotoxic chemotherapy. 2-6 June 2006, Atlanta, GA, USA.
    IDrugs : the investigational drugs journal, 2006, Volume: 9, Issue:8

    Topics: Clinical Trials as Topic; Cytarabine; Drug Combinations; Gossypol; Humans; Leukemia; Mastocytosis, Systemic; Molecular Structure; Pyrimidines; Pyrrolidines; Thionucleotides; Thymine; Trifluridine; Uracil

2006
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia.
    Gene, 2012, Jun-15, Volume: 501, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine

2012
Nilotinib and imatinib inhibit cytarabine cellular uptake: implications for combination therapy.
    Leukemia research, 2012, Volume: 36, Issue:10

    Topics: Benzamides; Cytarabine; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thymidine; Tumor Cells, Cultured

2012
ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells.
    Oncotarget, 2014, Jan-30, Volume: 5, Issue:2

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Cytarabine; Dasatinib; DNA Repair; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; K562 Cells; Mesoderm; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Thiazoles; Trans-Activators; Transcriptional Regulator ERG

2014
Secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation: a case report.
    Current medical research and opinion, 2020, Volume: 36, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Pyrimidines; Remission Induction; Transplantation, Autologous

2020